BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
The introduction of immune checkpoint blockade (ICB) and BRAF-MEK inhibitors has substantially improved outcomes in patients with metastatic melanoma. However, several challenging factors may hinder the efficacy of ICB in patients with symptomatic intracranial metastatic melanoma who are immunosuppr...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis Group
2021-06-01
|
| Reeks: | Melanoma Management |
| Onderwerpen: | |
| Online toegang: | https://www.futuremedicine.com/doi/10.2217/mmt-2020-0022 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|